Cell　receptor,　uPAR,　is　widely　considered　as　a　tumor　marker.　We　prepared　a　novel　tumor　targeting　drug　carrier　(ATF-HSA)　by　fusing　human　serum　albumin　(HSA)　with　a　uPAR　inhibitory　peptide　(amino-terminal　fragment　of　urokinase,　ATF)　and　successfully　loaded　a　photosensitizer,　mono-substituted-carboxy　phthalocyanine　zinc　(CPZ),　into　ATF-HSA　by　a　novel　strategy　to　form　a　molecular　complex　(ATF-HSA:CPZ).　ATF-HSA:CPZ　was　demonstrated　to　be　an　effective　photosensitizer　showing　remarkable　anti-tumor　effect　and,　at　the　same　time,　faster　liver　clearance　compared　to　other　types　of　photosensitizers.　Moreover,　ATF-HSA:CPZ　showed　much　higher　(100　)　fluorescence　compared　to　a　control　and　was　demonstrated　to　be　able　to　track　the　location　of　xenografted　tumor.